<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00546988</url>
  </required_header>
  <id_info>
    <org_study_id>DSMM V</org_study_id>
    <nct_id>NCT00546988</nct_id>
  </id_info>
  <brief_title>Multi Centre Trial of DSMM for Newly Diagnosed Multiple Myeloma up to 60 Years</brief_title>
  <official_title>Multizentrische Therapiestudie Des Multiplen Myeloms DSMM V Therapieoptimierungs-Studie Der Deutschen Studiengruppe Multiples Myelom für Patienten Bis 60 Jahre im Stadium II/III</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wuerzburg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Wuerzburg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is evaluating whether risk-stratification by the means of a chromosomal aberration
      provides a tool to discriminate between standard and high risk. Risk-adapted therapy is based
      on allogeneic stem-cell transplantation for high-risk subjects instead of a second autograft
      in patients with deletion of chromosome 13 who have an HLA-identical stem cell donor
      available.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The DSMM V protocol is to compare a consolidation treatment for standard-risk patients not
      displaying del(13) at initial diagnosis following two cycles of high-dose melphalan 200 mg/m²
      each supported by autologous stem cell retransfusion with interferon versus PEG-interferon.
      Patients with del(13) are screened for availability of a fully HLA-matched related or
      unrelated donor. If patient's informed consent is obtained additionally, he is scheduled to
      undergo an allogeneic SCT following the first cycle of high-dose melphalan. All other
      subjects are to proceed to a second course of high-dose melphalan similar to the
      standard-risk group. Initial cytoreduction is foreseen with four cycles of
      anthracycline-dexamethasone combination followed by combination therapy with
      ifosfamide/epirubicine/etoposide for stem-cell collection.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2001</start_date>
  <completion_date type="Anticipated">January 2008</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate after high-dose therapy</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate and treatment-related mortality after allogeneic transplantation</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Standard risk IFN</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Administration of interferon alpha as a maintenance treatment following autologous stem cell transplantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard risk PEGIFN</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Maintenance treatment with pegylated interferon following autologous stem cell transplantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High risk allo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Allogeneic stem cell transplantation from an HLA identical related or unrelated donor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High risk auto</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Second cycle of high-dose melphalan in subjects without an HLA-identical donor</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>allogeneic stem cell transplant</intervention_name>
    <arm_group_label>High risk allo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primary diagnosis of multiple myeloma

          -  Salmon-and-Durie stage II or III

          -  Less than or equal to 60 years

          -  Signed informed consent

        Exclusion Criteria:

          -  Relevant comorbidities

          -  Unable to adhere to study protocol

          -  Pregnancy

          -  Not received subject's informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hermann Einsele, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wuerzburg University Hospital, Dept. of Hematology and Oncology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hermann Einsele, M.D.</last_name>
    <phone>+49/931/201-0</phone>
    <phone_ext>70015</phone_ext>
    <email>einsele_h@klinik.uni-wuerzburg.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stefan Knop, M.D.</last_name>
    <phone>+49/931/201-0</phone>
    <phone_ext>70368</phone_ext>
    <email>knop_s@klinik.uni-wuerzburg.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medizinische Univ.-Klinik Graz</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Werner Linkesch, MD</last_name>
      <phone>++43(0)316/385-4086</phone>
      <email>werner.linkesch@kfunigraz.ac</email>
    </contact>
    <investigator>
      <last_name>Werner Linkesch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klin. Abt. für Onkologie, AKH Wien</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johannes Drach, MD</last_name>
      <email>heinz.gisslinger@akh-wien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Johannes Drach, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Staedtisches Klinikum</name>
      <address>
        <city>Augsburg</city>
        <zip>86156</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dept. of Hematology/Oncology, Charité Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10098</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Orhan Sezer, MD</last_name>
      <phone>030/450-513105</phone>
      <email>sezer@charite.de</email>
    </contact>
    <investigator>
      <last_name>Orhan Sezer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charité University Medicine</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Orhan Sezer, M.D.</last_name>
      <email>orhan.sezer@charite.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Nordwest</name>
      <address>
        <city>Frankfurt</city>
        <zip>60488</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Freiburg University Hospital</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monika Engelhardt, M.D.</last_name>
      <email>enghelhardtm@mm11ukl.uni-freiburg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Georg August University Hospital</name>
      <address>
        <city>Gottingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ernst-Moritz Arndt University Hospital</name>
      <address>
        <city>Greifswald</city>
        <zip>17478</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Martin-Luther University Hospital</name>
      <address>
        <city>Halle/Saale</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hans H Wolf, M.D.</last_name>
      <email>hans.wolf@medizin.uni-halle.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hannover Medical School</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dietrich Peest, M.D.</last_name>
      <phone>+49/511-532-0</phone>
      <phone_ext>-27765</phone_ext>
      <email>Peest.Dietrich@MH-Hannover.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saarland University Hospital</name>
      <address>
        <city>Homburg/Saar</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Pfreundschuh, M.D.</last_name>
      <phone>+49/6841-162-0</phone>
      <phone_ext>3003</phone_ext>
      <email>michael.pfreundschuh@uniklinik-saarland.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Schleswig-Holstein University Hospital</name>
      <address>
        <city>Lubeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mainz University Hospital</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dept. of Internal Medicine A, University Muenster</name>
      <address>
        <city>Muenster</city>
        <zip>48129</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Kropff, MD</last_name>
      <email>kropff@uni-muenster.de</email>
    </contact>
    <investigator>
      <last_name>Martin Kropff, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept. of Internal Medicine, Ludwig-Maximilian-University Munich</name>
      <address>
        <city>Munich</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Straka, MD</last_name>
      <phone>089/5160-2278</phone>
      <email>cstraka@medinn.med.uni-muenchen.de</email>
    </contact>
    <investigator>
      <last_name>Christian Straka, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar</name>
      <address>
        <city>Munich</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nuremberg Central Hospital</name>
      <address>
        <city>Nuremberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hannes Wandt, M.D.</last_name>
      <phone>+49/911/398-0</phone>
      <phone_ext>3090</phone_ext>
      <email>wandt@klinikum.nuernberg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oldenburg Hospital</name>
      <address>
        <city>Oldenburg</city>
        <zip>26133</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernd , Metzner</last_name>
      <phone>+49/441/403-0</phone>
      <phone_ext>2376</phone_ext>
      <email>metzner.bernd@klinikum-oldenburg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Katharinenhospital</name>
      <address>
        <city>Stuttgart</city>
        <zip>70173</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hans G Mergenthaler, M.D.</last_name>
      <phone>+49/711/253-0</phone>
      <phone_ext>2501</phone_ext>
      <email>hmergenthaler@buergerhospital.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Diakonissenkrankenhaus</name>
      <address>
        <city>Stuttgart</city>
        <zip>70176</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tubingen University Hospital</name>
      <address>
        <city>Tubingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katja Weisel, M.D.</last_name>
      <phone>+49/7071/29-0</phone>
      <phone_ext>-82711</phone_ext>
      <email>katja.weisel@med.uni-tuebingen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of Internal Medicine III, University of Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Liebisch, MD</last_name>
      <phone>0731/500-33809</phone>
      <email>peter.liebisch@medizin.uni-ulm.de</email>
    </contact>
    <investigator>
      <last_name>Peter Liebisch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ulm University Hospital</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Horst-Schmidt-Kliniken</name>
      <address>
        <city>Wiesbaden</city>
        <zip>65199</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Norbert Frickhofen, M.D.</last_name>
      <phone>+49/611/43-0</phone>
      <phone_ext>3009</phone_ext>
      <email>norbert.frickhofen@hsk-wiesbaden.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of Internal Medicine II, University of Wuerzburg</name>
      <address>
        <city>Wuerzburg</city>
        <zip>97070</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hermann Einsele, MD</last_name>
      <phone>+4993120170011</phone>
      <email>einsele_h@klinik.uni-wuerzburg.de</email>
    </contact>
    <investigator>
      <last_name>Volker Kunzmann, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stefan Knop, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.lymphome.de</url>
    <description>Site of the German association of the leading research groups in lymphoid malignancies</description>
  </link>
  <verification_date>October 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 17, 2007</study_first_submitted>
  <study_first_submitted_qc>October 17, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2007</study_first_posted>
  <last_update_submitted>October 17, 2007</last_update_submitted>
  <last_update_submitted_qc>October 17, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2007</last_update_posted>
  <keyword>primary treatment</keyword>
  <keyword>allogeneic stem-cell transplantation</keyword>
  <keyword>high-dose therapy</keyword>
  <keyword>cytogenetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

